
|Videos|July 29, 2013
Potential Cost Savings of Biosimilars
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
Advertisement
Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.
For more videos featuring Debbie Stern, please click on our
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves First At-Home Treatment Device for Depression
2
Integrated Specialty Pharmacy Services Improve Speed to Therapy and Clinical Outcomes
3
Tucatinib Enhances First-Line Maintenance Outcomes in HER2-Positive Metastatic Breast Cancer
4
Emerging Data from the DESTINY-Breast Trials Signal Shift in Standards of Care for HER2-Positive Breast Cancer
5

















































































































































































































